Wordt geladen...
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem. Sixteen healthy subjects received 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6 h for 5 doses, and were randomized to broncho...
Bewaard in:
| Gepubliceerd in: | Antimicrob Agents Chemother |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society for Microbiology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5826112/ https://ncbi.nlm.nih.gov/pubmed/29311084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01411-17 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|